ALID
Price
$0.01
Change
-$0.00 (-0.00%)
Updated
Aug 14 closing price
Capitalization
1.28M
ARSUF
Price
$20.03
Change
-$0.82 (-3.93%)
Updated
Oct 29 closing price
Capitalization
1.78B
Interact to see
Advertisement

ALID vs ARSUF

Header iconALID vs ARSUF Comparison
Open Charts ALID vs ARSUFBanner chart's image
Allied
Price$0.01
Change-$0.00 (-0.00%)
Volume$300
Capitalization1.28M
Fagron SA
Price$20.03
Change-$0.82 (-3.93%)
Volume$425
Capitalization1.78B
ALID vs ARSUF Comparison Chart in %
Loading...
ALID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALID vs. ARSUF commentary
Aug 17, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALID is a Buy and ARSUF is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 17, 2025
Stock price -- (ALID: $0.01 vs. ARSUF: $20.03)
Brand notoriety: ALID and ARSUF are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ALID: 8% vs. ARSUF: 100%
Market capitalization -- ALID: $1.28M vs. ARSUF: $1.78B
ALID [@Pharmaceuticals: Generic] is valued at $1.28M. ARSUF’s [@Pharmaceuticals: Generic] market capitalization is $1.78B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.3B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.74B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALID’s FA Score shows that 0 FA rating(s) are green whileARSUF’s FA Score has 1 green FA rating(s).

  • ALID’s FA Score: 0 green, 5 red.
  • ARSUF’s FA Score: 1 green, 4 red.
According to our system of comparison, ARSUF is a better buy in the long-term than ALID.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALID’s TA Score shows that 2 TA indicator(s) are bullish.

  • ALID’s TA Score: 2 bullish, 0 bearish.

Price Growth

ALID (@Pharmaceuticals: Generic) experienced а 0.00% price change this week, while ARSUF (@Pharmaceuticals: Generic) price change was 0.00% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +6.26%. For the same industry, the average monthly price growth was +68.76%, and the average quarterly price growth was +80.82%.

Industries' Descriptions

@Pharmaceuticals: Generic (+6.26% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARSUF($1.78B) has a higher market cap than ALID($1.28M). ARSUF YTD gains are higher at: 0.000 vs. ALID (-67.353). ARSUF has higher annual earnings (EBITDA): 158M vs. ALID (-2.93M). ARSUF has more cash in the bank: 116M vs. ALID (195K). ALID has less debt than ARSUF: ALID (6.71M) vs ARSUF (386M). ARSUF has higher revenues than ALID: ARSUF (872M) vs ALID (105K).
ALIDARSUFALID / ARSUF
Capitalization1.28M1.78B0%
EBITDA-2.93M158M-2%
Gain YTD-67.3530.000-
P/E RatioN/A17.97-
Revenue105K872M0%
Total Cash195K116M0%
Total Debt6.71M386M2%
FUNDAMENTALS RATINGS
ALID vs ARSUF: Fundamental Ratings
ALID
ARSUF
OUTLOOK RATING
1..100
3745
VALUATION
overvalued / fair valued / undervalued
1..100
87
Overvalued
25
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10057
PRICE GROWTH RATING
1..100
9072
P/E GROWTH RATING
1..100
10048
SEASONALITY SCORE
1..100
7555

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARSUF's Valuation (25) in the null industry is somewhat better than the same rating for ALID (87). This means that ARSUF’s stock grew somewhat faster than ALID’s over the last 12 months.

ARSUF's Profit vs Risk Rating (100) in the null industry is in the same range as ALID (100). This means that ARSUF’s stock grew similarly to ALID’s over the last 12 months.

ARSUF's SMR Rating (57) in the null industry is somewhat better than the same rating for ALID (100). This means that ARSUF’s stock grew somewhat faster than ALID’s over the last 12 months.

ARSUF's Price Growth Rating (72) in the null industry is in the same range as ALID (90). This means that ARSUF’s stock grew similarly to ALID’s over the last 12 months.

ARSUF's P/E Growth Rating (48) in the null industry is somewhat better than the same rating for ALID (100). This means that ARSUF’s stock grew somewhat faster than ALID’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALIDARSUF
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
82%
N/A
Momentum
ODDS (%)
N/A
N/A
MACD
ODDS (%)
N/A
N/A
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
69%
Bullish Trend 3 days ago
20%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 3 days ago
20%
Advances
ODDS (%)
N/A
N/A
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bullish Trend 3 days ago
78%
N/A
View a ticker or compare two or three
Interact to see
Advertisement
ALID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYBOX59.130.64
+1.09%
Rydex Biotechnology A
FBFQX12.710.01
+0.08%
Franklin Managed Income R
EVUAX20.92N/A
N/A
Allspring Util and Telecomms A
PALRX18.70-0.04
-0.21%
PGIM Balanced R
JUEPX26.92-0.10
-0.37%
JPMorgan US Equity R3

ALID and

Correlation & Price change

A.I.dvisor tells us that ALID and ABSCF have been poorly correlated (+16% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ALID and ABSCF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALID
1D Price
Change %
ALID100%
N/A
ABSCF - ALID
16%
Poorly correlated
N/A
ARSUF - ALID
8%
Poorly correlated
N/A
APNHY - ALID
7%
Poorly correlated
N/A
QNTM - ALID
4%
Poorly correlated
+0.45%
OGI - ALID
1%
Poorly correlated
-8.33%
More

ARSUF and

Correlation & Price change

A.I.dvisor tells us that ARSUF and GENPF have been poorly correlated (+23% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ARSUF and GENPF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARSUF
1D Price
Change %
ARSUF100%
N/A
GENPF - ARSUF
23%
Poorly correlated
N/A
AVCNF - ARSUF
11%
Poorly correlated
-2.28%
ALID - ARSUF
8%
Poorly correlated
N/A
BOIRF - ARSUF
1%
Poorly correlated
N/A
BIOVF - ARSUF
1%
Poorly correlated
N/A
More